Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1057071

registered interest
date	08/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Accident and Emergency Departments: North West
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to achieve the 95 per cent four-hour A&E waiting time in (a) Merseyside and (b) the North West.
tabling member constituency	Wallasey
tabling member printed	Ms Angela Eagle
uin	218762
answer	answer is ministerial correction date of answer 13/02/2019 answer text <p>The NHS Improvement Emergency Care Intensive Support Team is currently working to provide specialist support to systems across the North West region. Six trusts<sup>1 </sup>with challenged Emergency Departments routinely reporting ambulance-hospital handover delays are engaging with North West Ambulance Service as part of an initial 90-day improvement programme, which has now been extended further. In addition, eight trusts<sup>2 </sup>have received Urgent and Emergency Care capital investment this winter to make improvements to accident and emergency.</p><p> </p><p>NHS England’s ‘Operational and Planning Guidance for 2019/20’ sets out deliverables against key performance areas and the Government expects the National Health Service to deliver these actions in full as key steps towards fully recovering performance against core access standards.</p><p><strong> </strong></p><p>Notes:</p><p><sup>1</sup>Blackpool Teaching Hospitals NHS Foundation Trust, East Lancashire Hospital NHS Trust, Lancashire Teaching Hospitals Trust, Aintree University Hospital NHS Foundation Trust, Wirral University Teaching Hospital NHS Foundation Trust, and Wrightington, Wigan and Leigh NHS Foundation Trust.</p><p><sup>2</sup>Aintree University Hospital NHS Foundation Trust, Countess of Chester Hospital NHS Foundation Trust, Southport and Ormskirk Hospital NHS Trust, Wirral University Teaching NHS Foundation Trust, Lancashire Teaching Hospitals Trust, University Hospitals of Morecambe Bay, Stockport NHS Foundation Trust, and Tameside and Glossop Integrated Care NHS Foundation Trust.</p><p> </p><p> </p><p> </p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 13/02/2019 15:07:40 answering member 1585 label Biography information for Stephen Hammond
tabling member	491 label Biography information for Dame Angela Eagle

1057102

registered interest
date	08/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Genito-urinary Medicine
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 6 February 2019 to Question 216353 on sexual health clinicians, what the timeframe is for the publication of the findings of Baroness Harding's work.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	218807
answer	answer is ministerial correction date of answer 13/02/2019 answer text <p>Baroness Harding will present initial recommendations to the Department in spring 2019. A final workforce implementation plan will follow later in the year, taking into account the outcomes of the Spending Review.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 13/02/2019 15:03:17 answering member 1585 label Biography information for Stephen Hammond
tabling member	4036 label Biography information for Luciana Berger

1057104

registered interest
date	08/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Managers
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when his Department plans to publish new standards for NHS leaders.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	218809
answer	answer is ministerial correction date of answer 13/02/2019 answer text <p>In 2018, the Government had asked Tom Kark QC to carry out a review of the scope, operation and purpose of the Fit and Proper Person Requirement. The review, which was published on 6 February 2019, made seven recommendations, including to develop specified standards of competence that all directors, who sit on the Board, of any health providing organisation, should meet.</p><p> </p><p>The Government accepts this recommendation in principle, and has asked Baroness Dido Harding, the chair of the system-wide Workforce Implementation Steering Group, to look at how best to introduce new standards alongside other proposals on leadership and development of National Health Service managers, which is set out in the NHS Long Term Plan.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 13/02/2019 15:01:58 answering member 1585 label Biography information for Stephen Hammond
tabling member	4036 label Biography information for Luciana Berger

1056690

registered interest
date	07/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Multiple Sclerosis: Stem Cells
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, why my constituent’s stem cell treatment for MS has been halted due to NHS England’s decision to no longer allow GPs to refer patients for the treatment.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	218236
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>NHS England first published its commissioning policy in 2013, revised in 2015, which permits access to autologous haematopoietic stem cell transplant (HSCT) as a clinical option for some patients with multiple sclerosis (MS). The commissioning policy is available at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/01/b04-haematp-stem-cll-transplt.pdf" target="_blank">https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/01/b04-haematp-stem-cll-transplt.pdf</a></p><p> </p><p>As with any HSCT there are risks to the procedure and when considering this treatment for patients with MS the balance of risk and benefit must be carefully assessed for each patient. Neurologists and transplant doctors in the United Kingdom are guided by the recommendations of the European Society for Blood and Marrow Transplantation, published in 2012, and the guidance of the British Society of Blood and Marrow Transplantation when considering the suitability of transplant. These criteria restrict the use of autologous HSCT to a small group of MS patients with high levels of inflammatory activity despite one or more approved disease modifying therapies and very rare patients with 'malignant' forms of MS. Patients should be assessed by both MS and transplant specialists.</p><p> </p><p>Neurologist and transplant doctors should be guided by these recommendations and decisions related to a patient’s care are a matter for clinicians.</p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 218237 218238 question first answered 12/02/2019 16:26:03 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	1538 label Biography information for Rosie Cooper

1056691

registered interest
date	07/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Multiple Sclerosis: Stem Cells
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, for what reason Ms Helen Townsend’s Stem Cell treatment for MS was halted part way through as a result of NHS England's decision that GPs can longer refer people for the treatment and that patients must now be referred by a MS Neurology Specialist.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	218237
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>NHS England first published its commissioning policy in 2013, revised in 2015, which permits access to autologous haematopoietic stem cell transplant (HSCT) as a clinical option for some patients with multiple sclerosis (MS). The commissioning policy is available at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/01/b04-haematp-stem-cll-transplt.pdf" target="_blank">https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/01/b04-haematp-stem-cll-transplt.pdf</a></p><p> </p><p>As with any HSCT there are risks to the procedure and when considering this treatment for patients with MS the balance of risk and benefit must be carefully assessed for each patient. Neurologists and transplant doctors in the United Kingdom are guided by the recommendations of the European Society for Blood and Marrow Transplantation, published in 2012, and the guidance of the British Society of Blood and Marrow Transplantation when considering the suitability of transplant. These criteria restrict the use of autologous HSCT to a small group of MS patients with high levels of inflammatory activity despite one or more approved disease modifying therapies and very rare patients with 'malignant' forms of MS. Patients should be assessed by both MS and transplant specialists.</p><p> </p><p>Neurologist and transplant doctors should be guided by these recommendations and decisions related to a patient’s care are a matter for clinicians.</p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 218236 218238 question first answered 12/02/2019 16:26:03 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	1538 label Biography information for Rosie Cooper

1056692

registered interest
date	07/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Multiple Sclerosis: Stem Cells
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the effect of NHS England’s decision not to allow GPs to refer patients for Stem Cell treatment for MS on (a) patient health and (b) West Lancashire constituent Ms Townsend's (i) halted treatment and (b) recovery.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	218238
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>NHS England first published its commissioning policy in 2013, revised in 2015, which permits access to autologous haematopoietic stem cell transplant (HSCT) as a clinical option for some patients with multiple sclerosis (MS). The commissioning policy is available at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/01/b04-haematp-stem-cll-transplt.pdf" target="_blank">https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2015/01/b04-haematp-stem-cll-transplt.pdf</a></p><p> </p><p>As with any HSCT there are risks to the procedure and when considering this treatment for patients with MS the balance of risk and benefit must be carefully assessed for each patient. Neurologists and transplant doctors in the United Kingdom are guided by the recommendations of the European Society for Blood and Marrow Transplantation, published in 2012, and the guidance of the British Society of Blood and Marrow Transplantation when considering the suitability of transplant. These criteria restrict the use of autologous HSCT to a small group of MS patients with high levels of inflammatory activity despite one or more approved disease modifying therapies and very rare patients with 'malignant' forms of MS. Patients should be assessed by both MS and transplant specialists.</p><p> </p><p>Neurologist and transplant doctors should be guided by these recommendations and decisions related to a patient’s care are a matter for clinicians.</p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 218236 218237 question first answered 12/02/2019 16:26:03 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	1538 label Biography information for Rosie Cooper

1056721

registered interest
date	07/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Blood Diseases: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with pharmaceutical companies on access to medication for bleeding disorders in the event of the UK leaving the EU without a withdrawal agreement.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	218233
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>The Secretary of State for Health and Social Care discusses a wide range of issues with a number of stakeholders and other Government Departments.</p><p> </p><p>Medicines to treat bleeding disorders are in scope of our medicines contingency plans because these are licensed medicines. Contingency work for blood and blood components is being led by NHS Blood and Transplant.</p><p> </p><p>We understand that these medicines are vitally important to many people in this country. Our contingency plans include sensible mitigations for medicines that come to the United Kingdom from or via the European Union to ensure that the supply of medications for bleeding disorders and other essential medicines for patients is not disrupted. In developing our plans, we have received very good engagement from industry who share our aims of ensuring that the continuity of supply of medicines and medical products for patients is maintained and able to continue unimpeded after the UK leaves the EU on 29 March 2019.</p><p> </p><p>We have asked companies to ensure a minimum of six weeks additional supply over and above existing business as usual stocks by 29 March 2019, or to make provision for airfreight of medicines that cannot be stockpiled.</p><p> </p><p>That is why we are working to ensure we have sufficient roll-on, roll-off freight capacity on alternative routes to enable these vital products to continue to move freely in to the UK. Medicines and other medical products will be prioritised on these routes to ensure that the flow of all these products will continue unimpeded after 29 March 2019.</p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 12/02/2019 17:42:06 answering member 1585 label Biography information for Stephen Hammond
tabling member	1533 label Biography information for Dame Diana Johnson

1056732

registered interest
date	07/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress his Department has made on securing the availability of Orkambi on the NHS for patients with cystic fibrosis.
tabling member constituency	Sheffield, Brightside and Hillsborough
tabling member printed	Gill Furniss
uin	218344
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) and NHS England are leading the dialogue with Vertex Pharmaceuticals around access to their portfolio of cystic fibrosis medicines. It is critical that Vertex now re-engages fully with the NICE appraisal process and gives serious consideration to the portfolio deal offer that NHS England made at the end of July. This deal would provide immediate access for patients to all Vertex licensed medicines and future pipeline products once licensed and in advance of the individual NICE appraisals concluding.</p><p> </p><p>The Government fully supports the approach that NICE and NHS England are adopting. It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the National Health Service.</p><p> </p><p>NHS England has proposed its best offer ever for a drug. This offer, in the region of £500 million over five years, is the largest ever commitment of its kind in the 70-year history of the NHS and would guarantee immediate and expanded access to both Orkambi and the drug Kalydeco for patients who need it. Whilst it is disappointing that Vertex has not taken up NHS England’s offer, we are encouraged that there is continued dialogue between all parties.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/02/2019 15:33:24 answering member 4067 label Biography information for Steve Brine
tabling member	4571 label Biography information for Gill Furniss

1056733

registered interest
date	07/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cystic Fibrosis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the NHS is able to offer all treatment options for patients with cystic fibrosis.
tabling member constituency	Sheffield, Brightside and Hillsborough
tabling member printed	Gill Furniss
uin	218345
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>Specialised services for the support and treatment of patients with cystic fibrosis (CF) are commissioned nationally by NHS England. CF services are delivered in about 20 Paediatric Cystic Fibrosis Centres and about 20 Adult Cystic Fibrosis Centres. There are separate service specifications for adults and children. These specifications are important in clearly defining what NHS England expects to be in place for providers to offer evidence-based, safe and effective care and treatment. The support equity of access to a nationally consistent, high quality service.</p><p> </p><p>The specifications can be found via the following links:</p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2018/08/Cystic-fibrosis-adult.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2018/08/Cystic-fibrosis-adult.pdf</a></p><p> </p><p><a href="http://www.england.nhs.uk/wp-content/uploads/2018/07/a01Sb-spec-cystic-fibrosis-child.pdf" target="_blank">www.england.nhs.uk/wp-content/uploads/2018/07/a01Sb-spec-cystic-fibrosis-child.pdf</a></p><p> </p><p>In October 2017, the National Institute for Health and Care Excellence (NICE) published new guidance for the diagnosis and management of CF. This includes specific details on how to monitor the condition and manage the symptoms to improve quality of life. This guidance can be found via the following link:</p><p> </p><p><a href="http://www.nice.org.uk/guidance/ng78" target="_blank">www.nice.org.uk/guidance/ng78</a></p><p> </p><p>NICE is the organisation responsible for assessing the clinical and cost effectiveness of medicines for the National Health Service.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/02/2019 15:53:01 answering member 4067 label Biography information for Steve Brine
tabling member	4571 label Biography information for Gill Furniss

1056765

registered interest
date	07/02/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dental Services: Fees and Charges
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the press release entitled, Dentists welcome official investigation into fines hitting vulnerable NHS patients, published on 30 January 2019 by the British Dental Association; what steps his Department is taking to ensure that fear of receiving a fine for ticking the wrong box when claiming for free dental care does not discourage people from low income families from attending the dentist.
tabling member constituency	Barnsley Central
tabling member printed	Dan Jarvis
uin	218312
answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>All National Health Service dental practices are required to display a poster showing patient charges and to offer patients a free leaflet which sets out in detail who is entitled to free NHS dental services. Information on exemptions and support for people who are on a low income can also be found at the following link:</p><p> </p><p><a href="http://www.nhs.uk/healthcosts" target="_blank">www.nhs.uk/healthcosts</a></p><p> </p><p>Eligibility checks are carried out on claims received for exemption from NHS Dental Patient Charges. Where eligibility cannot be verified, patients are asked to confirm their eligibility or to pay the relevant dental charge plus a penalty charge. Patients are, however, able to challenge penalty charges they believe are unjustified.</p><p> </p><p>The Department, NHS Business Services Authority and NHS England have recognised the concern that some patients may not be clear on whether they are exempt from charges and has been working to further improve the information available to patients around eligibility. This includes promoting an easy read patient information booklet, creating an online eligibility checker and developing a national awareness campaign.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 218313 question first answered 12/02/2019 15:25:29 answering member 4067 label Biography information for Steve Brine
tabling member	4243 label Biography information for Dan Jarvis